Skip to Content
Author: The BCW

Regeneron Expands Collaboration on Gene Editing Therapies for Neurological and Muscular Diseases

BCW Member Regeneron Pharmaceuticals Inc. announced this week that it has expanded its research collaboration with Intellia Therapeutics, Inc. to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.

The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 systems adapted for viral vector delivery and designed to precisely modify a target gene. Under the terms of the expanded agreement, the companies will initially research two in vivo non-liver targets. Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach.

Each company will have the opportunity to lead potential development and commercialization of product candidates for one target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.

“To date, the widespread use of genetic medicines has generally been limited by the inability to deliver a genetic payload to cells of interest in the body beyond the liver,” said Dr. Aris Baras, senior vice president and co-head of Regeneron Genetic Medicines. “This expansion of our longstanding and productive collaboration with Intellia is taking advantage of new technology and innovations to unlock these opportunities.”

“We are excited to expand our successful collaboration with Regeneron to now accelerate the development of CRISPR-based therapies outside of the liver for the treatment of neurological and muscular diseases with significant unmet need,” added Intellia President and CEO Dr. John Leonard. “At Intellia, we are continuously innovating our editing and delivery solutions to realize the full potential of CRISPR gene editing as a new therapeutic modality. This collaboration is representative of our long-standing belief that the most groundbreaking solutions will come from selecting the best tools for each individual application, all of which are enabled by our industry-leading genome editing toolbox.”

Similar News Items

The BCW’s state advocacy program was actively engaged throughout the session including reaching out to legislators during the final last hours of the session. Countless memorandums of support and opposition on bills of importance to the business community were issued to the Legislature; and countless Zoom meetings were held. Additionally, the BCW was in constant contact with […]

Read Article

City, County and State officials held a press conference this week at Pugsley Park in Peekskill to discuss the city’s recent certification as a New York State Pro-Housing Community, its $10 million award from the Mid-Hudson Momentum Fund, and to celebrate the opening of Pugsley Park with a ribbon cutting. Over 50 people were in […]

Read Article

The BCW’s Government Action Council hosted its sixth annual Board of Legislators Reception on Tuesday, where BCW members shared their concerns with members of the Westchester County Board of Legislators. BOL Chair Vedat Gashi and BOL Vice Chair Jose Alvarado updated BCW members on the BOL’s ongoing activities, including preparing for next year’s County Executive […]

Read Article

Become A Member

Join the county’s largest and most influential business organization today.

The Business Council of Westchester is committed to helping businesses market, learn, advocate, and grow. Over 80 events and programs are offered every year, giving our members ample opportunity to connect and meet with businesses representatives in the Westchester community and beyond.
Back to top